1. Antisense oligonucleotide-mediated terminal intron retention of endoglin: A potential strategy to inhibit renal interstitial fibrosis.
- Author
-
Gerrits T, Dijkstra KL, Bruijn JA, Scharpfenecker M, Bijkerk R, and Baelde HJ
- Subjects
- Humans, Male, Fibronectins metabolism, Fibronectins genetics, Female, Actins metabolism, Actins genetics, Middle Aged, Animals, Collagen Type I genetics, Collagen Type I metabolism, Alternative Splicing, Fibroblasts metabolism, Fibroblasts pathology, RNA, Messenger genetics, RNA, Messenger metabolism, Mice, Cell Line, Fibrosis, Endoglin metabolism, Endoglin genetics, Oligonucleotides, Antisense pharmacology, Oligonucleotides, Antisense genetics, Introns genetics, Transforming Growth Factor beta1 metabolism, Transforming Growth Factor beta1 genetics, Kidney metabolism, Kidney pathology
- Abstract
TGF-β is considered an important cytokine in the development of interstitial fibrosis in chronic kidney disease. The TGF-β co-receptor endoglin (ENG) tends to be upregulated in kidney fibrosis. ENG has two membrane bound isoforms generated via alternative splicing. Long-ENG was shown to enhance the extent of renal fibrosis in an unilateral ureteral obstruction mouse model, while short-ENG inhibited renal fibrosis. Here we aimed to achieve terminal intron retention of endoglin using antisense-oligo nucleotides (ASOs), thereby shifting the ratio towards short-ENG to inhibit the TGF-β1-mediated pro-fibrotic response. We isolated mRNA from kidney biopsies of patients with chronic allograft disease (CAD) (n = 12) and measured total ENG and short-ENG mRNA levels. ENG mRNA was upregulated 2.3 fold (p < 0.05) in kidneys of CAD patients compared to controls, while the percentage short-ENG of the total ENG mRNA was significantly lower (1.8 fold; p < 0.05). Transfection of ASOs that target splicing regulatory sites of ENG into TK173 fibroblasts led to higher levels of short-ENG (2 fold; p < 0.05). In addition, we stimulated these cells with TGF-β1 and measured a decrease in upregulation of ACTA2, COL1A1 and FN1 mRNA levels, and protein expression of αSMA, collagen type I, and fibronectin. These results show a potential for ENG ASOs as a therapy to reduce interstitial fibrosis in CKD., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF